In September 2009 AlphaRx Inc signed an exclusive collaboration and licensing agreement with Riso Pharma Tech for the development of ARX606T, an early stage product candidate intended for wound treatment.
Under the agreement, AlphaRx grants Riso exclusive global rights (with the exception of Asia) to ARX606T, which makes use of AlphaRx’s proprietary formulation technology to deliver a safe and well known growth factor topically to patients with severe wounds and ulcers. Riso is responsible for all clinical development and commercialisation activities relating to ARX606T, granting double digit royalties to AlphaRx on future sales of the compound in all countries covered by the agreement.
